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Long-Term Outcome After Open (OR) and
Endovascular Repairs (EVAR) of Abdominal Aortic
Aneurysms (AAAs) in Matched Cohorts Using
Propensity Score Modeling
Ying Huang, Peter Gloviczki, Gustavo S. Oderich, Audra
A. Duncan, Kalra Manju, Mark D. Fleming, William S.
Harmsen, Catherine E. Dvorak, Thomas C. Bower.
Division of Vascular and Endovascular Surgery, Mayo
Clinic, Rochester, Minn
Objectives: To compare long-term outcomes after
OR vs EVAR of AAAs at a tertiary center.
Methods: Clinical data of consecutive AAA patients
treated electively between 2000 and 2011 were
retrospectively reviewed. Primary endpoint was all-cause
mortality, secondary endpoints were complications,
reinterventions and ruptures. Propensity score-based
matching included age, gender, year of intervention
and comorbidities was performed to compare
outcomes.
Results: There were 1350 matched cohorts (mean age
74 6 7 years). Thirty-day mortality was 1.3% after OR,
1.0% after EVAR (P ¼ .40). Early complications were
lower after EVAR (13% vs 25%; P < .0001). Mean
follow-up was 4.2 years (30 days-12.7 years). At 5 years,
all-cause mortality was lower, freedom from reintervention
higher after OR (23% vs 32%, 87% vs 74%); freedom from
complications the same (66%). In multi-variable analysis,
SVS-comorbidity score and age were associated with all-
cause mortality. Results were similar in 1791 unmatched
cohorts. There were 2 ruptures after OR, 8 after EVAR
(P ¼ .02).
Conclusions: Both elective OR and EVAR have low
early mortality, EVAR has fewer early complications.
Advanced age and comorbidities predict high late
mortality. This study failed to support long-term beneﬁts
of EVAR, since the procedure was associated with
increased rates of late all-cause mortality, reinterventions
and small but deﬁnite risk of late rupture.
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Matched (n ¼ 1350)
OR (n ¼ 675) EVAR (n ¼ 675)
Male (%) 583 (86) 580 (86)
30-day mortality (%) 9 (1.3) 7 (1.0)
5-year all-cause mortality (%) 23 32
5-year rupture (%) 0 0.54PS28.
Treatment of Type B Aortic Dissection in the
Endovascular Era
Mohsen Bannazadeh, Adewunmi Adeyemo, Yolanda
Munoz Maldonado, Jeffrey Altshuler, Marc Sakwa, O.
William Brown. William Beaumont Hospital, Royal Oak,
Mich
Objectives: The optimal management of Type B
Aortic Dissection (TBAD) remains controversial in the
era of endovascular therapies. This study reports the
outcomes of different treatment paradigms for TBAD.
Methods: A retrospective review was undertaken of
all patients with TBAD from June 2006 to June 2012.
Demographics, hospital course and follow up visits were
analyzed. Patients who underwent surgical interventions
were compared to those with medical therapy. Survival
rates and predictors of outcome were determined using
the Kaplan-Meier method with Cox proportional
hazards.
Results: Out of 276 consecutive patients who were
hospitalized during this period with a conﬁrmed
thoracic dissection, 134 (48%) had TBAD. Sixty-two
(46%) were women and the mean age was 66.4 6
14.9. Median follow-up was 22.4 (0, 184) month.
Thirty-ﬁve patients underwent surgical intervention
with 20 Thoracic Endovascular Aortic Repair (TEVAR)
and open surgery in 15. The overall 30-day mortality
was 7% and cumulative survival rates at 1 year, 3 years
and 5 years were 85% (79, 91), 68% (59, 78) and
57% (47, 69) with no difference between medical vs
surgical groups (P ¼ .8) and TEVAR vs open surgery
group (P ¼ 1.0). Sixty-six (50%) patients developed
aneurysmal expansion, which required surgical interven-
tion in 26 (hazard ratios [HR], 0.99; P ¼ .96). Malper-
fusion and rupture only occurred in 5 (HR, 1.57; P ¼
.54) and 5 (HR, 3.64; P ¼ .01) patients respectively.
Multivariate analysis for overall survival found renal
insufﬁciency (HR, 2.6; P ¼ .004) and age (HR, 1.06;
P < .0001) were associated with greatest mortality.
Intramural hematoma was not a signiﬁcant predictor
of survival (HR, 0.49; P ¼ .11).
Conclusions: Medical therapy remains the mainstay of
treating TBAD with low morbidity and acceptable survival
rates. Surgical interventions including TEVAR are indi-
cated in selected patients with malperfusion or aneurysmal
expansion.
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